Celsion Corporation (now Imunon, Inc.) — Form 10-Q summary
Filing and period: Unaudited quarterly report for the three and nine months ended September 30, 2017, filed November 14, 2017. The filing identifies the registrant as Celsion Corporation; the supplied company metadata uses Imunon, Inc.
Business context
Celsion was a development-stage oncology company with no product sales. Its lead candidate, ThermoDox, was in a Phase III trial for primary liver cancer; GEN-1 was being studied for ovarian cancer. The company also described preclinical programs and technology platforms. Reported revenue was licensing revenue under an existing Hisun agreement, not product revenue.
Key financial metrics
| Metric | Q3 2017 | Q3 2016 | Nine months 2017 | Nine months 2016 |
|---|---|---|---|---|
| Licensing revenue | $125,000 | $125,000 | $375,000 | $375,000 |
| Research and development | $3.35 million | $4.23 million | $9.87 million | $11.00 million |
| General and administrative | $1.17 million | $1.50 million | $4.29 million | $4.89 million |
| Operating loss | $4.40 million | $5.60 million | $13.79 million | $15.52 million |
| Net loss | $5.67 million | $6.41 million | $15.72 million | $16.66 million |
| Net loss per share | $0.70 | $3.22 | $3.04 | $9.27 |
Loss per share is shown as a loss. Weighted-average shares increased substantially year over year, and the filing’s share data reflects a 14-for-1 reverse stock split. Revenue was small relative to operating costs; conventional operating margins are not meaningful for this pre-revenue development company.
- Cash and liquidity: Cash and cash equivalents were $2.69 million at September 30, 2017, versus $2.62 million at December 31, 2016. Current assets were $2.77 million and current liabilities $6.00 million, a $3.22 million working-capital deficit.
- Cash flows: Nine-month operating cash use was $12.43 million. Investing activities provided $1.76 million, mainly from investment-security maturities and release of a letter-of-credit deposit. Financing activities provided $10.74 million, including equity and warrant proceeds, partly offset by $2.60 million of debt principal and end-of-term payments. Cash increased by $61,000 over the period.
- Debt and other liabilities: The Hercules loan was repaid in full in June 2017; no notes payable remained at September 30. The balance sheet included a $12.52 million EGEN earn-out milestone liability and $2.63 million of deferred revenue.
- Assets and equity: Total assets were $26.00 million, including $20.25 million of in-process research and development (IPR&D). Stockholders’ equity was $5.29 million; accumulated deficit was $257.10 million.
Changes versus prior comparable period
- Q3 net loss narrowed by about $0.74 million; nine-month net loss narrowed by about $0.94 million. Lower R&D and G&A expenses contributed, while the comparisons also reflect non-cash valuation and impairment items.
- Nine-month R&D declined 10%, although OPTIMA study costs rose to $4.9 million from $4.4 million as enrollment increased. Lower costs in other clinical programs and manufacturing helped offset that rise.
- Cash use from operations improved to $12.43 million from $13.72 million in the prior-year period. Cash at period-end was lower than the prior year’s $4.18 million reported for September 30, 2016.
- The company recognized a $2.52 million non-cash impairment of GBM-related IPR&D. It also recorded a $1.25 million Q3 non-cash gain from reducing the estimated EGEN earn-out liability; the nine-month gain was $0.67 million.
- During 2017, the company issued equity and warrants and repriced certain warrants; a $0.35 million deemed dividend was recorded for the nine months. The Hercules debt repayment eliminated the remaining loan balance.
Outlook, commentary and risks
- Management’s liquidity outlook: After September 30, warrant exercises generated about $17.0 million gross proceeds and an October 31 offering generated $6.6 million gross proceeds. Management said the combined $23.6 million of October gross proceeds plus September-end cash and investments was expected to fund operations well into the second quarter of 2019. This was an estimate, not a guarantee; the company said it would need additional funding to continue development and had no other committed financing source beyond an available $7.5 million ATM facility.
- Clinical outlook: The OPTIMA Phase III trial had enrolled over 67% of its planned 550 patients, with enrollment expected to finish by mid-2018 based on then-current rates. The independent monitoring committee recommended continuing the trial after its review of the first 50% of patients. The filing also discusses retrospective HEAT subgroup analyses, but the prior HEAT Phase III trial failed its primary progression-free-survival endpoint; subgroup findings are not definitive confirmation of efficacy.
- GEN-1: The company reported encouraging early OVATION findings, including responses and surgical outcomes, and expected to submit a next-phase protocol to the FDA by year-end 2017. These were small early-stage study results and do not establish clinical benefit.
- Principal risks: Continued operating losses, dependence on additional and potentially dilutive financing, clinical-trial failure or delay, regulatory uncertainty, reliance on third-party clinical and manufacturing partners, competition, intellectual-property and licensing exposure, and possible Nasdaq listing noncompliance. The company also disclosed that its lead candidate previously failed a Phase III primary endpoint.
- Other disclosures: The filing reported no legal proceedings and no material changes to internal control over financial reporting; management concluded disclosure controls were effective at a reasonable-assurance level. No off-balance-sheet financing arrangements were reported.
Important facts for investors to verify
- Confirm the registrant and security identity: this 2017 filing is for Celsion Corporation, despite the request metadata naming Imunon, Inc.
- Check the exact net proceeds, fees and warrant terms for the October 2017 financings; the filing cites gross proceeds and different descriptions of the October warrant exercise proceeds in places.
- Review subsequent filings for actual cash runway, quarterly cash burn, and any later financing or changes to management’s second-quarter-2019 runway estimate.
- Track OPTIMA enrollment, interim and final results, and whether trial outcomes support the retrospective HEAT subgroup rationale.
- Assess the GBM IPR&D impairment assumptions and the contingent EGEN earn-out liability, including whether further impairments or milestone payments occur.
- Verify dilution from outstanding and newly issued shares, warrants, options, and the ATM facility; the filing reports 16,062,341 common shares outstanding as of November 13, 2017.